Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nepafenac Eye Drops for Congenital Hereditary Endothelial Dystrophy
NCT04843839Phase 2Unknown
- Sponsor
- L V Prasad Eye Institute
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nepafenac in congenital hereditary endothelial dystrophy (CHED), sponsored by L V Prasad Eye Institute. Status: unknown.
02
Drugs
nepafenac
03
Conditions
congenital hereditary endothelial dystrophy (CHED)
Beyond the preview
Go deeper on NCT04843839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843839.